{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:37Z","timestamp":1793228257269,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medjaden Academy & Research Foundation for Young Scientists","award":["MJR202410127"],"award-info":[{"award-number":["MJR202410127"]}]},{"name":"Fundamental Research Program of Shanxi Province","award":["202203021212011"],"award-info":[{"award-number":["202203021212011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01941-3","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T01:41:43Z","timestamp":1764034903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of a Treg-related gene signature for predicting prognosis and immunosuppression in skin cutaneous melanoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Chao","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruina","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanfen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"1","key":"1941_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10151","key":"1941_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971\u201384.","journal-title":"Lancet"},{"issue":"3","key":"1941_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"1941_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"23","key":"1941_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238984","volume":"21","author":"K Eddy","year":"2020","unstructured":"Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21(23):8984.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1941_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14(7):466.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1941_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10143-024-02595-7","volume":"47","author":"MA Habibi","year":"2024","unstructured":"Habibi MA, Mirjani MS, Ahmadvand MH, Delbari P, Eftekhar MS, Ghazizadeh Y, et al. Anti-PD-1\/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis. Neurosurg Rev. 2024;47(1):434.","journal-title":"Neurosurg Rev"},{"issue":"10","key":"1941_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","volume":"35","author":"S Mart\u00edn-Lluesma","year":"2024","unstructured":"Mart\u00edn-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G, et al. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol. 2024;35(10):860\u201372.","journal-title":"Ann Oncol"},{"key":"1941_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103988","volume":"186","author":"R Venzel","year":"2023","unstructured":"Venzel R, Campos MCP, de Oliveira LP, Dan Lins RV, Siena \u00c1DD, Mesquita KT, et al. Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: past, present and future. Crit Rev Oncol Hematol. 2023;186:103988.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1941_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982986","volume":"13","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, Ke S, Chen J, Qin Z, Zhang W, Yuan Y, et al. Foxp3+ regulatory T cells and the immune escape in solid tumours. Front Immunol. 2022;13:982986.","journal-title":"Front Immunol"},{"issue":"12","key":"1941_CR11","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.3390\/ijms25126377","volume":"25","author":"VA G\u00e2ta","year":"2024","unstructured":"G\u00e2ta VA, Pa\u0219ca A, Roman A, Muntean MV, Morariu D\u0218, Bonci EA, et al. The expression of forkhead box P3 T regulatory lymphocytes as a prognostic factor in malignant melanomas. Int J Mol Sci. 2024;25(12):6377.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1941_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjd.13172","volume":"172","author":"B Azzimonti","year":"2015","unstructured":"Azzimonti B, Zavattaro E, Provasi M, Vidali M, Conca A, Catalano E, et al. Intense Foxp3+CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+\/Foxp3+ CD25+ ratio. Br J Dermatol. 2015;172(1):64\u201373.","journal-title":"Br J Dermatol"},{"key":"1941_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105084","volume":"112","author":"JH Cho","year":"2021","unstructured":"Cho JH, Lim YC. Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2021;112:105084.","journal-title":"Oral Oncol"},{"issue":"1","key":"1941_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010200","volume":"18","author":"A Jorapur","year":"2022","unstructured":"Jorapur A, Marshall LA, Jacobson S, Xu M, Marubayashi S, Zibinsky M, et al. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog. 2022;18(1):e1010200.","journal-title":"PLoS Pathog"},{"issue":"6","key":"1941_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s10120-023-01418-w","volume":"26","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wei D, Deguchi Y, Xu W, Tian R, Liu F, et al. Ppar\u03b4 dysregulation of CCL20\/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023;26(6):904\u201317.","journal-title":"Gastric Cancer"},{"key":"1941_CR16","doi-asserted-by":"publisher","first-page":"1626708","DOI":"10.3389\/fimmu.2025.1626708","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Zhang L, Liu R, Xu C, Tang H, Zou Y, et al. CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer. Front Immunol. 2025;16:1626708.","journal-title":"Front Immunol"},{"key":"1941_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110093","volume":"118","author":"YS Ibrahim","year":"2023","unstructured":"Ibrahim YS, Amin AH, Jawhar ZH, Alghamdi MA, Al-Awsi GRL, Shbeer AM, et al. \u201cTo be or not to Be\u201d: regulatory T cells in melanoma. Int Immunopharmacol. 2023;118:110093.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1941_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/08923973.2025.2504906","volume":"47","author":"GS Gill","year":"2025","unstructured":"Gill GS, Kharb S, Goyal G, Das P, Kurdia KC, Dhar R, et al. Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance. Immunopharmacol Immunotoxicol. 2025;47(4):485\u2013507.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1941_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16313","author":"M Attias","year":"2024","unstructured":"Attias M, Piccirillo CA. The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors. Br J Pharmacol. 2024. https:\/\/doi.org\/10.1111\/bph.16313.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1941_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","volume":"42","author":"SN Geels","year":"2024","unstructured":"Geels SN, Moshensky A, Sousa RS, Murat C, Bustos MA, Walker BL, et al. Interruption of the intratumor CD8+ T cell: treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 2024;42(6):1051-1066.e7.","journal-title":"Cancer Cell"},{"key":"1941_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702726","volume":"12","author":"EN Scott","year":"2021","unstructured":"Scott EN, Gocher AM, Workman CJ, Vignali DAA. Regulatory t cells: barriers of immune infiltration into the tumor microenvironment. Front Immunol. 2021;12:702726.","journal-title":"Front Immunol"},{"issue":"10","key":"1941_CR22","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1002\/tox.24247","volume":"39","author":"W Huang","year":"2024","unstructured":"Huang W, Kim BS, Zhang Y, Lin L, Chai G, Zhao Z. Regulatory t cells subgroups in the tumor microenvironment cannot be overlooked: their involvement in prognosis and treatment strategy in melanoma. Environ Toxicol. 2024;39(10):4512\u201330.","journal-title":"Environ Toxicol"},{"key":"1941_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.782216","volume":"12","author":"Q Sun","year":"2021","unstructured":"Sun Q, Li Y, Yang X, Wu X, Liu Z, Mou Y, et al. Identification and validation of 17-lncRNA related to regulatory T cell heterogeneity as a prognostic signature for head and neck squamous cell carcinoma. Front Immunol. 2021;12:782216.","journal-title":"Front Immunol"},{"issue":"6","key":"1941_CR24","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1002\/tox.24214","volume":"39","author":"X Lv","year":"2024","unstructured":"Lv X, Ma W, Miao X, Hu S, Xie H. Navigating colorectal cancer prognosis: a Treg-related signature discovered through single-cell and bulk transcriptomic approaches. Environ Toxicol. 2024;39(6):3512\u201322.","journal-title":"Environ Toxicol"},{"issue":"15","key":"1941_CR25","doi-asserted-by":"publisher","first-page":"13523","DOI":"10.1007\/s00432-023-05187-y","volume":"149","author":"L Xu","year":"2023","unstructured":"Xu L, Liu M, Lian J, Li E, Dongmin C, Li X, et al. A prognostic nomogram for predicting recurrence-free survival of stage I-III colon cancer based on immune-infiltrating Treg-related genes. J Cancer Res Clin Oncol. 2023;149(15):13523\u201343.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"1941_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"1941_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.56","volume":"2","author":"K Ito","year":"2013","unstructured":"Ito K, Murphy D. Application of ggplot2 to pharmacometric graphics. CPT Pharmacom Syst Pharmacol. 2013;2(10):e79.","journal-title":"CPT Pharmacom Syst Pharmacol"},{"key":"1941_CR28","unstructured":"BioSenior. (2023). ggvolcano (Version 0.1.4) [R package]. CRAN. https:\/\/CRAN.R-project.org\/package=ggvolcano"},{"issue":"5","key":"1941_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jemermed.2015.01.008","volume":"49","author":"SR Wilcox","year":"2015","unstructured":"Wilcox SR. Wilcox reply to sever and vanholder. J Emerg Med. 2015;49(5):709.","journal-title":"J Emerg Med"},{"key":"1941_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"1941_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab108","volume":"22","author":"A Jia","year":"2021","unstructured":"Jia A, Xu L, Wang Y. Venn diagrams in bioinformatics. Brief Bioinform. 2021;22(5):bbab108.","journal-title":"Brief Bioinform"},{"key":"1941_CR32","unstructured":"Kassambara A, Kosinski M, Biecek P. Survminer: Drawing survival curves using 'ggplot2' (Version 0.4.9) [R package]. CRAN. 2021. https:\/\/CRAN.R-project.org\/package=survminer"},{"issue":"1","key":"1941_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0730-1","volume":"11","author":"S Engebretsen","year":"2019","unstructured":"Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenetics. 2019;11(1):123.","journal-title":"Clin Epigenetics"},{"key":"1941_CR34","unstructured":"Gordon M, Lumley T. forestplot: Advanced forest plot using 'grid' graphics (Version 2.0.1) [R package]. CRAN. 2021. https:\/\/CRAN.R-project.org\/package=forestplot."},{"issue":"1\u20132","key":"1941_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363.","journal-title":"J Immunol Methods"},{"issue":"2","key":"1941_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337\u201344.","journal-title":"Biometrics"},{"issue":"23","key":"1941_CR37","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):2229\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"1941_CR38","doi-asserted-by":"publisher","first-page":"1786888","DOI":"10.1080\/2162402X.2020.1786888","volume":"9","author":"Y Pico de Coa\u00f1a","year":"2020","unstructured":"Pico de Coa\u00f1a Y, Wolodarski M, van der Haar \u00c0I, Nakajima T, Rentouli S, Lundqvist A, et al. PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. Oncoimmunology. 2020;9(1):1786888.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1941_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"1941_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260\u201370.","journal-title":"Clin Cancer Res"},{"key":"1941_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327.","journal-title":"Semin Cancer Biol"},{"key":"1941_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104258","volume":"145","author":"AL Shergold","year":"2019","unstructured":"Shergold AL, Millar R, Nibbs RJB. Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade. Pharmacol Res. 2019;145:104258.","journal-title":"Pharmacol Res"},{"key":"1941_CR43","doi-asserted-by":"publisher","first-page":"1268188","DOI":"10.3389\/fimmu.2023.1268188","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu X, Zhou Z, Cao Q, Chen Y, Gong J, Zhang Q, et al. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review. Front Immunol. 2023;14:1268188.","journal-title":"Front Immunol"},{"issue":"1","key":"1941_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43556-021-00038-z","volume":"2","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Y, Liu S, Wang H, Zhu J, Ou L, et al. Targeting regulatory T cells for immunotherapy in melanoma. Mol Biomed. 2021;2(1):11.","journal-title":"Mol Biomed"},{"issue":"5","key":"1941_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri.2017.143","volume":"18","author":"CA Dendrou","year":"2018","unstructured":"Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18(5):325\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1941_CR46","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N Mcgranahan","year":"2017","unstructured":"Mcgranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259\u201371.","journal-title":"Cell"},{"issue":"2","key":"1941_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12282-022-01419-0","volume":"30","author":"J Chu","year":"2023","unstructured":"Chu J, Min KW, Kim DH, Son BK, Kim HS, Jung US, et al. High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach. Breast Cancer. 2023;30(2):259\u201370.","journal-title":"Breast Cancer"},{"issue":"12","key":"1941_CR48","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/ni.3025","volume":"15","author":"X Xu","year":"2014","unstructured":"Xu X, Araki K, Li S, Han JH, Ye L, Tan WG, et al. Autophagy is essential for effector CD8 (+) T cell survival and memory formation. Nat Immunol. 2014;15(12):1152\u201361.","journal-title":"Nat Immunol"},{"issue":"3","key":"1941_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","volume":"17","author":"J Wei","year":"2016","unstructured":"Wei J, Long L, Yang K, Guy C, Shrestha S, Chen Z, et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol. 2016;17(3):277\u201385.","journal-title":"Nat Immunol"},{"key":"1941_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-immunol-041015-055427","volume":"34","author":"A Larange","year":"2016","unstructured":"Larange A, Cheroutre H. Retinoic acid and retinoic acid receptors as pleiotropic modulators of the immune system. Annu Rev Immunol. 2016;34:369\u201394.","journal-title":"Annu Rev Immunol"},{"issue":"47","key":"1941_CR51","doi-asserted-by":"publisher","first-page":"46632","DOI":"10.1074\/jbc.M309159200","volume":"278","author":"C Tellez","year":"2003","unstructured":"Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem. 2003;278(47):46632\u201342.","journal-title":"J Biol Chem"},{"issue":"3","key":"1941_CR52","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/gb-2012-13-3-r17","volume":"13","author":"ML \u00c4nk\u00f6","year":"2012","unstructured":"\u00c4nk\u00f6 ML, M\u00fcller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, et al. The RNA-binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol. 2012;13(3):R17.","journal-title":"Genome Biol"},{"issue":"5","key":"1941_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1684\/ejd.2019.3636","volume":"29","author":"A Smirnov","year":"2019","unstructured":"Smirnov A, Anemona L, Montanaro M, Mauriello A, Annicchiarico-Petruzzelli M, Campione E, et al. Transglutaminase 3 is expressed in basal cell carcinoma of the skin. Eur J Dermatol. 2019;29(5):477\u201383.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1941_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41419-024-06626-5","volume":"15","author":"K Zhou","year":"2024","unstructured":"Zhou K, Wu C, Cheng W, Zhang B, Wei R, Cheng D, et al. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation. Cell Death Dis. 2024;15(4):252.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1941_CR55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.seizure.2013.03.006","volume":"22","author":"G Li","year":"2013","unstructured":"Li G, Nowak M, Bauer S, Schlegel K, Stei S, Allenh\u00f6fer L, et al. Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes. Seizure. 2013;22(6):462\u20136.","journal-title":"Seizure"},{"issue":"4","key":"1941_CR56","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1755-148X.2012.01018.x","volume":"25","author":"SI Anghel","year":"2012","unstructured":"Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, et al. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell Melanoma Res. 2012;25(4):482\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"1941_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88373-x","volume":"15","author":"J Wu","year":"2025","unstructured":"Wu J, Chen L, Wen P. CRIP1 inhibits cutaneous melanoma progression through TFAM-mediated mitochondrial biogenesis. Sci Rep. 2025;15(1):4298.","journal-title":"Sci Rep"},{"issue":"12","key":"1941_CR58","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1136\/gutjnl-2022-329349","volume":"72","author":"X Liu","year":"2023","unstructured":"Liu X, Tang R, Xu J, Tan Z, Liang C, Meng Q, et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-\u03baB\/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut. 2023;72(12):2329\u201343.","journal-title":"Gut"},{"issue":"7","key":"1941_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011315","volume":"13","author":"D Mallardo","year":"2025","unstructured":"Mallardo D, Fordellone M, Bailey M, White A, Simeone E, Festino L, et al. Gene-expression signature predicts autoimmune toxicity in metastatic melanoma. J Immunother Cancer. 2025;13(7):e011315.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1941_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105384","volume":"23","author":"J T\u00edm\u00e1r","year":"2022","unstructured":"T\u00edm\u00e1r J, Lad\u00e1nyi A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction. Int J Mol Sci. 2022;23(10):5384.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1941_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M, et al. CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J Transl Med. 2023;21(1):610.","journal-title":"J Transl Med"},{"issue":"17","key":"1941_CR62","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.3390\/ijms25179345","volume":"25","author":"D Mallardo","year":"2024","unstructured":"Mallardo D, Fordellone M, White A, Vowinckel J, Bailey M, Sparano F, et al. A combined proteomic and transcriptomic signature is predictive of response to anti-PD-1 treatment: a retrospective study in metastatic melanoma patients. Int J Mol Sci. 2024;25(17):9345.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1941_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory t cells in cancer immunotherapy. Cell Res. 2017;27(1):109\u201318.","journal-title":"Cell Res"},{"issue":"4","key":"1941_CR64","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"issue":"7","key":"1941_CR65","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1941_CR66","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","volume":"30","author":"EM Shevach","year":"2009","unstructured":"Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636\u201345.","journal-title":"Immunity"},{"issue":"5899","key":"1941_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271\u20135.","journal-title":"Science"},{"issue":"4","key":"1941_CR68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"8","key":"1941_CR69","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00262-020-02842-y","volume":"70","author":"V Sasidharan Nair","year":"2021","unstructured":"Sasidharan Nair V, Saleh R, Toor SM, Cyprian FS, Elkord E. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunol Immunother. 2021;70(8):2103\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1941_CR70","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1541-7786.MCR-22-0684","volume":"21","author":"SE Fenton","year":"2023","unstructured":"Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, et al. Targeting ULK1 decreases IFN\u03b3-mediated resistance to immune checkpoint inhibitors. Mol Cancer Res. 2023;21(4):332\u201344.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1941_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-025-03453-0","volume":"44","author":"F De Mitri","year":"2025","unstructured":"De Mitri F, Giansanti M, Melaiu O, Haas D, Ebert S, Tumino N, et al. Inhibition of autophagy enhances the antitumor efficacy of T\/CAR T cell against neuroblastoma. J Exp Clin Cancer Res. 2025;44(1):185.","journal-title":"J Exp Clin Cancer Res"},{"key":"1941_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106141","volume":"129","author":"Y Park","year":"2022","unstructured":"Park Y, Jang J. Prospect of ULK1 modulators in targeting regulatory T cells. Bioorg Chem. 2022;129:106141.","journal-title":"Bioorg Chem"},{"issue":"16","key":"1941_CR73","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.7150\/jca.86838","volume":"14","author":"F Yuan","year":"2023","unstructured":"Yuan F, Sun Y, Dai GC, Yao Q, Zhou YB, Zang YC, et al. Comprehensive analysis of prognostic value and immune infiltration of TFAP2 family members in bladder cancer from database and FFPE sample. J Cancer. 2023;14(16):3050\u201365.","journal-title":"J Cancer"},{"issue":"3","key":"1941_CR74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","volume":"146","author":"L Salmena","year":"2011","unstructured":"Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. 2011;146(3):353\u20138.","journal-title":"Cell"},{"issue":"7483","key":"1941_CR75","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature12986","volume":"505","author":"Y Tay","year":"2014","unstructured":"Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344\u201352.","journal-title":"Nature"},{"issue":"11","key":"1941_CR76","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nm.3981","volume":"21","author":"M Huarte","year":"2015","unstructured":"Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253\u201361.","journal-title":"Nat Med"},{"key":"1941_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-immunol-020711-075013","volume":"30","author":"RM O'Connell","year":"2012","unstructured":"O\u2019Connell RM, Rao DS, Baltimore D. Microrna regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295\u2013312.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"1941_CR78","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.immuni.2015.05.017","volume":"42","author":"A Mehta","year":"2015","unstructured":"Mehta A, Zhao JL, Sinha N, Marinov GK, Mann M, Kowalczyk MS, et al. The microRNA-132 and microRNA-212 cluster regulates hematopoietic stem cell maintenance and survival with age by buffering FOXO3 expression. Immunity. 2015;42(6):1021\u201332.","journal-title":"Immunity"},{"key":"1941_CR79","doi-asserted-by":"publisher","first-page":"543","DOI":"10.18632\/oncotarget.28447","volume":"14","author":"V Feichtenschlager","year":"2023","unstructured":"Feichtenschlager V, Zheng YJ, Ho W, Chen L, Callanan C, Chen C, et al. Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment. Oncotarget. 2023;14:543\u201360.","journal-title":"Oncotarget"},{"issue":"1","key":"1941_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3644","volume":"26","author":"X Jia","year":"2024","unstructured":"Jia X, Feng H, He S, Chen X, Feng H, Chen M, et al. HGF facilitates methylation of MEG3, potentially implicated in vemurafenib resistance in melanoma. J Gene Med. 2024;26(1):e3644.","journal-title":"J Gene Med"},{"key":"1941_CR81","volume":"2017","author":"X Chen","year":"2017","unstructured":"Chen X, Gao G, Liu S, Yu L, Yan D, Yao X, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. BioMed Res Int. 2017;2017:7038579.","journal-title":"BioMed Res Int"},{"issue":"3","key":"1941_CR82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","volume":"24","author":"G Arun","year":"2018","unstructured":"Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24(3):257\u201377.","journal-title":"Trends Mol Med"},{"issue":"3","key":"1941_CR83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. Microrna therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01941-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:03:17Z","timestamp":1764079397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01941-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1941"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01941-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not involve any animal or human experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and human rights"}}],"article-number":"35"}}